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Abstract
Background: Alzheimer's disease is the leading cause of dementia in the elderly and the third most common
cause of death in the United States. A vast number of genes regulate Alzheimer’s disease, including Presenilin 1
(PSEN1). Multiple studies have attempted to locate novel variants in the PSEN1 gene that affect Alzheimer's disease
status. A recent study suggested that one of these variants, PSEN1 E318G (rs17125721), significantly affects
Alzheimer's disease status in a large case–control dataset, particularly in connection with the APOEε4 allele.
Methods: Our study looks at the same variant in the Cache County Study on Memory and Aging, a large
population-based dataset. We tested for association between E318G genotype and Alzheimer’s disease status by
running a series of Fisher’s exact tests. We also performed logistic regression to test for an additive effect of E318G
genotype on Alzheimer’s disease status and for the existence of an interaction between E318G and APOEε4.
Results: In our Fisher’s exact test, it appeared that APOEε4 carriers with an E318G allele have slightly higher risk for
AD than those without the allele (3.3 vs. 3.8); however, the 95 % confidence intervals of those estimates overlapped
completely, indicating non-significance. Our logistic regression model found a positive but non-significant main
effect for E318G (p = 0.895). The interaction term between E318G and APOEε4 was also non-significant (p = 0.689).
Conclusions: Our findings do not provide significant support for E318G as a risk factor for AD in APOEε4 carriers.
Our calculations indicated that the overall sample used in the logistic regression models was adequately powered
to detect the sort of effect sizes observed previously. However, the power analyses of our Fisher’s exact tests
indicate that our partitioned data was underpowered, particularly in regards to the low number of E318G carriers,
both AD cases and controls, in the Cache county dataset. Thus, the differences in types of datasets used may help
to explain the difference in effect magnitudes seen. Analyses in additional case–control datasets will be required to
understand fully the effect of E318G on Alzheimer's disease status.
Keywords: Alzheimer’s disease, Presenilin, Rare variants, Epistasis
Background
Alzheimer’s disease (AD) is the most common type of
dementia in the elderly and the third most common
cause of death in the United States [1]. It is notoriously
difficult to diagnose, with highly variable clinical symp-
toms and no existing laboratory test able to detect it
conclusively [2]. The two primary markers of AD, amyl-
oid plaques and neurofibrillary tangles, can usually only
be detected at autopsy.
AD’s clinical complexity is compounded by its com-
plex etiology, and a vast number of genes have been
implicated [3, 4]. Ridge et. al. recently estimated that
33% of AD phenotypic variation can be explained by
genetic mutations, and suggested that 25% of the total
variation may be explained by currently-unknown rare
mutations [5]. Ebbert et. al. further demonstrated that
epistasis plays a critical role in Alzheimer’s and may
explain a significant proportion of the missing herit-
ability [6]. The Presenilin 1 gene (PSEN1) is one of
the genes known to affect Alzheimer’s disease risk
[7]; it codes for a transmembrane protein that forms
the core of the gamma secretase complex, an enzyme
* Correspondence: kauwe@byu.edu
1Department of Biology, Brigham Young University, Provo, UT, USA
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Hippen et al. BMC Genomics 2016, 17(Suppl 3):438
DOI 10.1186/s12864-016-2786-z
that cleaves amyloid precursor protein into β-
amyloid peptides [8]. PSEN1 mutations have been
shown to affect amyloid precursor protein cleavage,
resulting in amyloid β-42 peptides. These longer,
more hydrophobic fragments tend to form into pla-
ques that are associated with damaged brain tissue,
making amyloid β-42 levels an important patho-
logical marker for AD [9].
Another relevant biomarker in pre-symptomatic
Alzheimer’s is the tau protein, which is responsible
for stabilizing microtubules in the brain. However,
phosphorylated tau (ptau) is less able to perform this
function, allowing the microtubules to become disor-
ganized and form neurofibrillary tangles [10]. An in-
creased phosphorylation of tau has been associated
with increased amyloid deposition into plaques [11].
Fagan et. al. observed that the ratio of amyloid β-42
to ptau is associated with cognitive decline [12] and
thus the two combined could make a probable bio-
marker for preclinical Alzheimer’s disease.
Multiple studies have identified novel variants in the
PSEN1 gene that affect Alzheimer’s disease status [13–
15]. A recent study by Benitez et. al. found that one such
mutation, PSEN1 E318G (rs17125721), increases the ra-
tio of tau to Aβ-42 and ptau to Aβ-42 in the cerebro-
spinal fluid; as discussed previously, these ratios can be
an important indicator of a preclinical AD phenotype
[16]. The Benitez et. al. study also suggests a potential
gene-gene interaction between PSEN1 and APOE. Spe-
cifically, it suggests that E318G carriers who are also
heterozygous carriers of the APOEε4 allele have a similar
AD risk as individuals who are homozygous for APOEε4
and twice the risk of those heterozygous for APOEε4
without the E318G allele.
Gene-gene interactions are an important element of
AD etiology [17–20], and an interaction between PSEN1
E318G and APOE could have an important function in
the genetic pathways of the disease, but the existence of
such an effect has not yet been validated in other data-
sets. Here, we attempt to replicate the effects of E318G
in connection to APOE on Alzheimer’s status in a
population-based dataset.
Methods
Samples for this study came from the Cache County
Study on Memory Health and Aging. When the study
began in 1994, the 5092 subjects therein represented ap-
proximately 90% of all residents age 65 and older in
Cache County, Utah. Case–control status was deter-
mined through a series of clinical dementia evaluations
and cognitive assessments, including the Modified Mini-
Mental State Exam-Revised [21]. These assessments
were administered every three years over a period of
twelve years. Cases were defined as those subjects
meeting criteria determined by the National Institute of
Neurological Disorders and Stroke–Alzheimer’s disease
and Related Disorders Association to indicate possible
or probable AD. Individuals with dementia only showed
symptoms of late-onset AD with no other comorbid
forms of dementia. Cognitively normal individuals were
free of any symptoms of AD and other comorbid forms
of dementia at all stages of screening. There were no
early-onset Alzheimer’s cases in the dataset. Additional
information about data collection and phenotype deter-
mination has been reported previously [22].
We genotyped the PSEN1 E318G locus (rs17125721)
for 3420 individuals using a custom TaqMan assay. Ge-
notypes were called based on cluster analyses using the
default settings in the TaqMan genotyper software
(Thermo Fisher). The marker had a call rate of greater
than 98%. Of the 3420 individuals, 478 were clinically
ascertained Alzheimer’s disease cases and 2942 were
cognitively normal controls.
We excluded all individuals for whom APOE and
E318G genotyping or Alzheimer's disease case/control
status were unavailable. We used Fisher’s exact test to
calculate odds ratios for effect of APOEε4 status on AD
risk in E318G carriers and E318G non-carriers. To de-
termine if the effect of E318G on AD risk was different
for APOEε4 homozygotes versus heterozygotes we calcu-
lated the odds ratios for each combination of E318G car-
rier/non-carrier status and their number of APOEε4
alleles (0, 1 or 2).
We used the odds ratios described above to calcu-
late the synergy factor between E318G status and
APOEε4 status. Synergy factors are the ratio of the
observed and expected odds ratios for the two inter-
acting SNPs. Assuming there is no synergy between
the SNPs (i.e., the SNPs are independent); the ex-
pected odds ratio then equals the product of the indi-
vidual odds ratios. The synergy factor is calculated by
dividing the observed odds ratio by the expected odds
ratio for the interacting SNPs. A synergy factor that
deviates from 1 suggests a statistical interaction be-
tween the SNPs [19],[20]. We calculated the synergy
factor of E318G and APOEε4 to test further the exist-
ence of an interaction between these SNPs and their
effect on Alzheimer’s disease risk.
We ran a logistic regression model using case/control
status as the response, with E318G, age, gender, and
APOEε4 positive or negative status as covariates. We
also included an interaction between APOE and E318G
to test the finding by Benitez et. al. that carriers of both
E318G and APOEε4 were more at risk of developing AD
than carriers of either mutation alone. We then tested
the E318G mutation's effect on AD status independent
of APOEε4 in a second logistic regression model by
using only APOEε3 homozygotes in the Cache County
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dataset (n = 1916). In this model, we included E318G,
age, and gender as covariates.
To determine if we had sufficient statistical power to ob-
serve an effect of E318G on AD status in connection to
APOEε4, we calculated the minimum discernible effect size
of E318G in all individuals in the Cache County Study
using a power analysis [23]. We used sample size, E318G
exposure, and AD status to find the smallest effect size we
could detect with 80% power. If we had sufficient power to
detect the kind of odds ratios that were found by Benitez
et. al., then we could be confident that our sample size was
large enough to discover the same effect if it existed in the
Cache County dataset. Then, to determine if we had
enough power to see an effect of E318G on AD status inde-
pendent of APOEε4, we calculated the minimum discern-
ible effect size of E318G in APOEε3 homozygotes.
Results
It would appear that APOEε4 carriers with an E318G allele
have slightly higher risk for AD than those without the al-
lele (3.3 vs. 3.8); however, the 95 % confidence intervals of
these two estimates overlap completely (Table 1). Similarly,
comparisons of odds ratios for AD risk based on E318G
and number of APOEε4 alleles revealed that E318G carriers
with one APOEε4 allele were at a higher—but non-
significant—risk for AD (OR = 3.5, CI = 1.0-12.7, p = 0.043)
compared to APOEε4 heterozygotes who did not carry the
E318G allele (OR = 3.0, CI = 2.4 - 3.7, p < 2.2 × 10−16).
E318G carriers with two APOEε4 alleles had a larger odds
ratio (OR = 9.1, CI = 0.1 - 759.3, p = 0.197) than non-
carriers (OR = 7.5, CI = 4.6-12.0, p = 2.4 × 10–15), but the
confidence interval was extremely large and the result was
not significant (Table 2). Based on our synergy factor calcu-
lation, the odds ratios obtained from the Fisher's exact test
comparing Alzheimer’s disease risk based on APOEε4 pres-
ence or absence did not give evidence of a significant inter-
action between E318G and APOEε4 (Synergy factor = 1.17,
p = 0.78).
In our first logistic regression model, which considered
all individuals in the dataset and included an interaction
term between APOEε4 and E318G, we found a positive
but non-significant main effect for E318G (p = 0.895).
The interaction term between E318G and APOEε4 was
also non-significant (p = 0.689). The second logistic re-
gression model, which included only those who were
homozygous for the non-disease-causing APOEε3 allele,
also did not have a significant additive effect for E318G
(p = 0.826). Our power analysis indicated that, with a
sample size of 3420, we had 80% power to detect an
odds ratio of 1.9 or bigger if one existed (alpha = 0.05).
For the second logistic regression model, with a sample
size of 1916 APOEε3 heterozygotes, we had 80% power
to detect an odds ratio of 2.4 or larger (alpha = 0.05).
Discussion
We failed to detect significant associations with E318G and
AD as described by Benitez et al. While the direction of our
results are consistent with those reported by Benitez et al.,
our results provide little support that the E318G allele in-
creases risk for AD in APOEε4 carriers (Tables 1 and 2).
Further studies will be necessary to clarify the effects of
E318G on AD. The lack of replication in rare variant
Table 1 Results from Fisher’s exact test. The odds ratio for Alzheimer’s Disease risk for individuals who were carriers of E318G and
APOEε4 was higher than the odds ratio for those who only carried APOEε4, but the confidence intervals overlap
Alzheimer’s risk based on E318G status and APOEε4 Status
Strata Cases Controls P value OR (95 % CI) Power
E318G + APOEε4 (+) 8 20 0.0172 3.8 (1.1–13.3) 0.66
APOEε4 (−) 8 77
E318G – APOEε4 (+) 253 765 <2.2 × 10−16 3.3 (2.7–4.0) 1.0
APOEε4 (−) 209 2080
Table 2 Results from Fisher’s exact test. The odds ratios observed were higher for E318G+ individuals than E318G– individuals with
the same number of APOEε4 alleles, but the 95 % confidence intervals for these groups overlap
Alzheimer’s risk based on E318G status and number of APOEε4 Alleles
Strata Cases Controls P value OR (95 % CI) Power
E318G + APOEε44 1 1 0.197 9.1 (0.1–759.3) 0.04
APOEε4 (+) 7 19 0.043 3.5 (1.0–12.7) 0.16
APOEε4 (−) 8 77
E318G – APOEε44 36 48 2.4 × 10−15 7.5 (4.6–12.0) 1.0
APOEε4 (+) 217 717 <2.2 × 10−16 3.0 (2.4–3.7) 1.0
APOEε4 (−) 209 2080
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associations and with interactions can be difficult to inter-
pret, as these associations are particularly sensitive to gen-
etic and phenotypic heterogeneity. While our calculations
indicate the overall sample is adequately powered to detect
the sort of effect sizes observed by Benitez et al., the power
analyses of our Fisher’s exact tests indicate that our study of
the partitioned data was underpowered, particularly in
regards to the low number of E318G carriers, both AD
cases and controls, in the Cache county dataset. Differences
in ascertainment and population may have presented chal-
lenges for replication in the Cache County Study of the
finding of Benitez et al. As such, we believe that further
analyses using samples that are more similar to those used
in the original report will be necessary to determine the sig-
nificance of the interaction between the APOEε4 allele and
E318G on Alzheimer's disease risk.
Conclusions
Rare variants play a significant role in Alzheimer’s disease
phenotypic variance. The number of possible variants with
a functional effect, as well as the existence of epistatic inter-
actions, means that many further studies will be required to
fully characterize rare variants’ roles. Our study did not find
any evidence of PSEN1 E318G having a significant effect on
Alzheimer’s disease status, but it is possible that significance
could be found using larger, case–control datasets. More
studies involving greater number of rare variants, examined
both independently and in combination, will help to make
the genetic etiology of Alzheimer’s disease clearer and more
clinically actionable.
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